LEVIPHARM - Company finances
- The company is late in submitting financial data for the previous financial year.
- Latest financial data up to 2024-12-31.
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 2,790 | 9,072 | 6,000 | 5,010 | 2,540 | 4,230 | 3,960 |
| Profit before tax | 2,343 | 3,096 | -668 | 1,613 | - | - | - |
| Net profit | 2,323 | 2,976 | -668 | 1,556 | -957 | -1 | -4,775 |
| Equity | 2,170 | 5,146 | 4,478 | 6,034 | 5,077 | 5,077 | 341 |
| Liabilities | 411 | 0 | 285 | 342 | 540 | 1,603 | 883 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current assets | 2,581 | 8,767 | 4,763 | 6,376 | 5,617 | 6,680 | 1,224 |
| Total assets | 2,581 | 8,767 | 4,763 | 6,376 | 5,617 | 6,680 | 1,224 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | - | 106 | 145 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | +225.2% | -33.9% | -16.5% | -49.3% | +66.5% | -6.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 90.0% | 33.9% | -14.0% | 24.4% | -17.0% | 0.0% | -390.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 107.1% | 57.8% | -14.9% | 25.8% | -18.8% | 0.0% | -1400.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 83.3% | 32.8% | -11.1% | 31.1% | -37.7% | 0.0% | -120.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 84.0% | 34.1% | -11.1% | 32.2% | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.2 | - | 0.1 | 0.1 | 0.1 | 0.3 | 2.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 2,790 | 9,072 | 6,000 | 5,010 | 2,540 | 4,230 | 3,960 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
LEVIPHARM - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-01-22 | 2025-01-22 | 316.50 |
| 2025-01-16 | 2025-01-21 | 315.35 |
| 2025-01-02 | 2025-01-15 | 118.82 |
| 2024-12-22 | 2024-12-31 | 118.82 |
| 2024-12-17 | 2024-12-20 | 118.82 |
| 2024-11-18 | 2024-11-20 | 118.82 |
| 2024-01-16 | 2024-01-22 | 100.57 |
| 2023-12-18 | 2023-12-19 | 100.57 |
| 2023-04-18 | 2023-04-18 | 100.51 |
| 2021-12-16 | 2021-12-20 | 58.18 |
LEVIPHARM - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.